Impacts9d
Understanding the Monthly Cost of Semaglutide: What to Expect
Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...
CMS to seek Medicare negotiations on Ozempic price
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
The Hill13d
How Trump’s Greenland demands could impact Ozempic costs
Danish multinational pharmaceutical giant Novo Nordisk is the sole owner of semaglutide, the active ingredient in both ...
American College of Cardiology14d
New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...
Forbes15d
Best Hoka Coupons: Save Up To 20% This Weekend
Hoka’s best-selling sneakers are known for their supportive fit and bold, colorful designs. Several of the brand’s styles are featured in our sneaker shopping guides, including an updated ...
verywellhealth24d
Another Study Links Ozempic to a Rare Eye Condition That Can Cause Vision Loss
A July 2024 study published in JAMA Ophthalmology found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a higher risk of a rare eye condition known as "eye stroke," or non ...
Business Insider1mon
A woman who lost 100 pounds on semaglutide shared 3 ways the holiday season has changed — including not feeling the need to diet in the new year
The holiday season used to be conflicting for Ashley Dunham. It was a joyous time to get together with family and friends over delicious food and drinks. But as someone who wanted to lose weight ...
American College of Cardiology1mon
Who to Select For Treatment With Semaglutide: A Look at the SELECT Trial
At the American Heart Association's (AHA) Scientific Sessions 2023, the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) trial 1 was presented demonstrating ...